These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28122407)

  • 1. Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface.
    Bitton E; Courey C; Giancola P; Diaconu V; Wise J; Wittich W
    Clin Exp Optom; 2017 Nov; 100(6):583-589. PubMed ID: 28122407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bimatoprost in the treatment of eyelash hypotrichosis.
    Law SK
    Clin Ophthalmol; 2010 Apr; 4():349-58. PubMed ID: 20463804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latisse (bimatoprost) for enhancement of eyelashes.
    Flaharty PM; Flaharty KK; Gorman L
    Insight; 2014; 39(3):24-6. PubMed ID: 25195339
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of hypotrichosis of the eyelashes: focus on bimatoprost.
    Fagien S
    Plast Surg Nurs; 2015; 35(2):82-91. PubMed ID: 26020474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.
    Fagien S; Walt JG; Carruthers J; Cox SE; Wirta D; Weng E; Beddingfield FC
    Aesthet Surg J; 2013 Aug; 33(6):789-98. PubMed ID: 23873891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimatoprost 0.03% solution (latisse) for eyelash enhancement.
    Med Lett Drugs Ther; 2009 Jun; 51(1313):43-4. PubMed ID: 19478690
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management of trichotillomania with bimatoprost.
    Peabody T; Reitz S; Smith J; Teti B
    Optom Vis Sci; 2013 Jun; 90(6):e167-71. PubMed ID: 23645373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
    Glaser DA; Hossain P; Perkins W; Griffiths T; Ahluwalia G; Weng E; Beddingfield FC
    Br J Dermatol; 2015; 172(5):1384-94. PubMed ID: 25296533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes.
    Wester ST; Lee WW; Shi W
    Ophthalmology; 2010 May; 117(5):1024-31. PubMed ID: 20163864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth.
    Yoelin S; Walt JG; Earl M
    Dermatol Surg; 2010 May; 36(5):638-49. PubMed ID: 20384751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.
    Steinsapir KD; Steinsapir SMG
    Dermatol Surg; 2021 May; 47(5):658-665. PubMed ID: 33625141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
    Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
    Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical bimatoprost 0.03% and iatrogenic eyelid and orbital lipodystrophy.
    Sira M; Verity DH; Malhotra R
    Aesthet Surg J; 2012 Sep; 32(7):822-4. PubMed ID: 22942109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hypotrichosis of the eyelashes: Focus on bimatoprost.
    Fagien S
    Clin Cosmet Investig Dermatol; 2010 Apr; 3():39-48. PubMed ID: 21437058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latisse: empirical discovery yields treatment for sparse eyelashes.
    Woodson SA
    Nurs Womens Health; 2009 Jun; 13(3):243-8. PubMed ID: 19523139
    [No Abstract]   [Full Text] [Related]  

  • 17. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia.
    Barrón-Hernández YL; Tosti A
    Expert Opin Investig Drugs; 2017 Apr; 26(4):515-522. PubMed ID: 28264599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tear film osmolarity in patients treated for glaucoma or ocular hypertension.
    Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
    Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimatoprost-induced chemical blepharoplasty.
    Sarnoff DS; Gotkin RH
    J Drugs Dermatol; 2015 May; 14(5):472-7. PubMed ID: 25942665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.